Lung cancer (LC) is the tumor responsible for the highest mortality worldwi...
Status
Recruiting
Location
Research Site
Start Date
2023-07-28
Trial ID
NCT06068049
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
PHASE1
This multicenter, open-label, Phase I study will evaluate the safety, effic...
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
PHASE1
This is an open-label, multicenter, Phase Ib study to determine the maximum...